Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Achieve (ACHV) Q2 Net Loss Hits $12.7M

TheMotleyFool 
0 0 07.08.25
Achieve (ACHV) Q2 Net Loss Hits $12.7M
 

Achieve Life Sciences (NASDAQ:ACHV), a late-stage biopharmaceutical firm focused on therapies for nicotine dependence, released its second-quarter fiscal 2025 results on August 7, 2025. The headline news: Achieve successfully filed its anticipated NDA for cytisinicline, its lead investigational therapy for smoking cessation, and secured a new commercialization partnership. Achieve reported a GAAP net loss per share of $(0.37), closely in line with the consensus GAAP EPS estimate of $(0.37). As expected for a pre-commercial biotech firm, revenue was zero. The company had $55.4 million in cash, cash equivalents, and marketable securities, boosted by recent financing. Overall, Achieve advanced essential milestones.

Source: Analyst estimates for the quarter provided by FactSet.

Achieve Life Sciences is a biopharmaceutical company developing new treatments for nicotine dependence, with a focus on its investigational drug cytisinicline. Cytisinicline is a plant-derived compound designed to help people stop smoking or vaping by targeting nicotine receptors in the brain.

Continue reading


Source Fool.com

Electro Power Systems S.A. Stock

Show more
Like: 0
ACHV
Share

Comments

Not a member yet? Sign up for free!